Avrok Biosciences’ Post

Dive into our latest study: "Evaluation of BCR Control Cell-lines and Synthetic Controls." Explore how Cellecta's DriverMap™ AIR technology enhances the accuracy and sensitivity of immune receptor profiling, essential for innovative immunotherapy approaches. 🧫🔍 Discover how our collaboration with the FDA and our use of synthetic spike-in controls set new standards in the evaluation of immune response. Don't miss out on the cutting-edge advancements we're bringing to immunological research! Read the detailed findings here! https://loom.ly/xEO-Qzc #Cellecta #ImmuneProfiling #BCRControl #MedicalResearch #InnovationInHealthcare

Whether creating standardized bacterial packages or pioneering new drugs targeting microbiome-mechanisms, your research will transform patient care. Go for it! Patients are waiting for you. #Science #Microbiome #MedicalInnovation #Research https://lnkd.in/dET4AwHs

Don't worry if you are new to the mRNA world, you're fashionably on time for the innovation opportunities! There are still many areas in mRNA-LNP industry with significant potential for innovation and growth that have not yet been fully explored or capitalized on. Here are a few examples: ➡ While mRNA-LNP delivery systems have shown great promise, there is still room for improvement in terms of enhancing delivery efficiency, target specificity, stability and safety. ➡ Despite significant progress, there is still a need to optimize the safety profile of LNPs, particularly concerning potential immune responses, cytotoxicity, and off-target effects. ➡ Developing imaging techniques, such as near-infrared fluorescence imaging or magnetic resonance imaging, that can visualize and track LNPs in real-time will improve our understanding of LNP behavior in living organisms and help monitor the biodistribution, pharmacokinetics, and pharmacodynamics of LNPs. ➡ There is growing interest in combining LNPs with immunomodulatory agents, such as adjuvants or immune checkpoint inhibitors, to enhance the efficacy of nucleic acid-based vaccines and immunotherapies. ➡ Developing scalable manufacturing processes and tailored formulations can accommodate individual patient characteristics and therapeutic needs. ➡ Addressing the challenges associated with the clinical translation of LNP-based therapies, including scalability, reproducibility, and regulatory considerations. There's a significant imperative to explore these areas that require improvement and have the potential to transform mRNA therapy approaches for the better. What are the other white spaces you can add to this list? #mRNA #LNP #Innovation #Whitespaces #mRNAtherapy

Laboratory optimization results in faster #diagnosis, less time to correct treatment, overall better care, and better #qualityoflife for patients. But elucidating the financial impact of the #clinical #laboratory can be difficult. In this paper, we show that bringing the #HemoSIL #HIT antibody assay in-house reduced overall length of stay and resulted in significant financial savings for our institution. This paper was also featured as a #CAP Selected Abstract for June 2024! https://lnkd.in/gE_3T-ai

Microbio Co Ltd's exploratory clinical trial showed a threefold increase in the objective response rate for the MS-20-Keytruda group compared to Keytruda alone: https://lnkd.in/dHh_qDUb

📣 New article published by the team of Silvia Gregori! The review authored by Konstantina Morali, Gloria Giacomello, Michela Vuono and Silvia Gregori provides an overview of current knowledge on the role of tolerogenic dendritic cells (tolDC) in health and disease. The review is focused on (i) IL-10 production, (ii) functional characterization of in vitro generated tolDC, (iii) molecular and metabolic changes occurring in tolDC induced by tolerogenic agents, (iv) clinical applications of tolDC-based therapy, and on (v) new perspectives in the generation of effective tolDC. Congratulations to all co-authors! Link to the paper: https://lnkd.in/dfE-nWcz #HaDEA, #EU, #immunotherapy, #tolerogenicdendriticcells

The phase 1/2 Mobilize trial is evaluating the safety and efficacy of mRNA-4359

The phase 1/2 Mobilize trial is evaluating the safety and efficacy of mRNA-4359

Isotype control antibodies are critical in ensuring accurate results in immunological assays like ELISA and flow cytometry. They help distinguish specific binding from non-specific background, giving you reliable data.

The FDA, co-led by CDER and CBER in collaboration with CDRH, plans to establish the Rare Disease Innovation Hub. The Hub will: 1) Connect the rare disease community with the FDA, aiding in the navigation of relevant FDA processes. 2) Enhance collaboration within the FDA to address scientific, clinical, and policy issues in rare disease product development. 3) Advance regulatory science with workstreams on novel endpoints, biomarker development, innovative trial design, real-world evidence, and statistical methods.